αv integrin inhibitors and cancer therapy

Current Opinion in Investigational Drugs

Volumn 4, Issue 6, 2003, Pages 722-731

  Tucker, Gordon C ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

v integrins; Angiogenesis; Cilengitide; Drug targeting; Tumor imaging; Vitaxin

Indexed keywords

ALPHAIIBBETA3 INTEGRIN; ALPHAIIBBETA3 INTEGRIN ANTAGONIST; ALPHAV INTEGRIN INHIBITOR; ALPHAVBETA3 INTEGRIN ANTAGONIST; ALPHAVBETA5 INTEGRIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID 4C; ATN 161; CD51 ANTIGEN; CILENGITIDE; DOXORUBICIN; EMD 85189; FIBRINOGEN RECEPTOR ANTAGONIST; IMMUNOLOGIC AGENT; INTEGRIN; MONOCLONAL ANTIBODY LM 609; N ACETYLPHENYLALANYLHISTIDYLSERYLCYSTEINYLASPARAGINAMIDE; NANOPARTICLE; RP 697; SB 273005; TACHYPLESIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONJUGATE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOXICITY; HUMAN; IMMUNOTHERAPY; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; METASTASIS; NONHUMAN; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRIN ALPHAV; INTEGRINS; NEOPLASMS;

EID: 0042165831     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Gadek TR, Nicholas JB: Small molecule antagonists of proteins. Biochem Pharmacol (2003) 65(1):1-8.
2. Brakebusch C, Bouvard D, Stanchi F, Sakai T, Fässler R: Integrins in invasive growth. J Clin Invest (2002) 109(8):999-1006.
3. Hood JD, Cheresh DA: Role of integrins in cell invasion and migration. Nat Rev Cancer (2002) 2(2):91-100.
4. De Arcangelis A, Georges-Labouesse E: Integrin and ECM functions: Roles in vertebrate development. Trends Genet (2000) 16(9):389-395.
5. Mousa SA: Anti-integrin as novel drug-discovery targets: Potential therapeutic and diagnostic implications. Curr Opin Chem Biol (2002) 6(4):534-541.
6. Leclerc JR: Platelet glycoprotein IIb/IIIa antagonists: Lessons learned from clinical trials and future directions. Crit Care Med (2002) 30(5 Suppl):S332-S340.
7. Hynes RO: Integrins: Bidirectional, allosteric signaling machines. Cell (2002) 110(6):673-687.
8. Tucker GC: Inhibitors of integrins. Curr Opin Pharmacol (2002) 2(4):394-402.
9. Kerr JS, Slee AM, Mousa SA: The αv integrin antagonists as novel anticancer agents: An update. Expert Opin Investig Drugs (2002) 11(12):1765-1774.
10. Mehlen P, Bredesen DE: Dependence receptors: Links between apoptosis, nervous system development and control of tumorigenesis. Bull Cancer (2000) 87(7-8):537-541.
11. Rüegg C, Dormond O, Foletti A: Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: Which side to target? Endothelium (2002) 9(3):151-160.
12. Haubner R, Finsinger D, Kessler H: Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew Chem Int Ed (1997) 36(13-14):1374-1389.
13. Cannon CP: The evolving story of oral platelet glycoprotein IIb/IIIa receptor inhibitors. Curr Opin Cardiovasc Pulm Renal Invest Drugs (2000) 2(2):114-123.
14. Trikha M, Timar J, Zacharek A, Nemeth JA, Cai Y, Dome B, Somlai B, Raso E, Ladanyi A, Honn KV: Role for β3 integrins in human melanoma growth and survival. Int J Cancer (2002) 101(2):156-167.
15. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT: Multiple roles for platelet GPIIb/IIIa and αvβ3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res (2002) 62(10):2824-2833.
16. Cheresh DA: Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA (1987) 84(18):6471-6475.
17. Marcinkiewicz C, Rosenthal LA, Mosser DM, Kunicki TJ, Niewiarowski S: Immunological characterization of eristostatin and echistatin binding sites on αIIbβ3 and αvβ3 integrins. Biochem J (1996) 317(Pt 3):817-825.
18. Rosok MJ, Yelton DE, Harris LJ, Bajorath J, Hellström K-E, Hellström I, Cruz GA, Kristensson K, Lin H, Huse WD, Glaser SM: A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. J Biol Chem (1996) 271(37):22611-22618.
19. Mikecz K: Vitaxin applied molecular evolution. Curr Opin Investig Drugs (2000) 1(2):199-203.
20. Rader C, Cheresh DA, Barbas CF III: A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries. Proc Natl Acad Sci USA (1998) 95(15):8910-8915.
21. Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, Huse WD, Watkins JD: Stepwise in vitro affinity maturation of Vitaxin, an αvβ3-specific humanized mAb. Proc Natl Acad Sci USA (1998) 95(11):6037-6042.
22. Ward BK, Heinrichs JH, Mancini M, Xu Y, Langermann S, Kiener P, Tice DA, Woessner R: Inhibition of growth of human melanoma xenografts by Vitaxin, a humanized monoclonal antibody specific for αvβ3. Proc Annu Meet Am Assoc Cancer Res (2003) 44:Abs 6430.
23. Rader C, Popkov M, Neves JA, Barbas CF III: Integrin αvβ3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. FASEB J (2002) 16(14):2000-2002.
24. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, Reyes G, Piulats J: In vivo therapy of malignant melanoma by means of antagonists of αv integrins. Int J Cancer (2000) 87(5):716-723.
25. Mitjans F, Sander D, Adán J, Sutter A, Martinez JM, Jäggle C-S, Moyano JM, Kreysch HG, Piulats J, Goodman SL: An anti-αv-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci (1995) 108(8):2825-2838. In this report, the results of an antibody-dependent cellular cytotoxicty (ADCC) assay in vitro suggest that the antibody acts directly by perturbing the function of the αv integrins. ADCC may not be the main mechanism of action of antibodies against αv integrins.
26. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA: Targeted anti-angiogenic therapy for cancer using vitaxin: A humanized monoclonal antibody to the integrin αvβ3. Clin Cancer Res (2000) 6(8):3056-3061. In this initial phase I study in 14 evaluable patients, Vitaxin induced seven disease stabilizations and a partial response in one patient with liver metastases from a leiomyosarcoma.
27. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS: Pilot study of vitaxin - An angiogenesis inhibitor- in patients with advanced leiomyosarcomas. Cancer (2001) 92(5):1347-1348. In a subsequent phase II trial of 15 patients presenting with advanced leiomyosarcoma, weekly treatments with Vitaxin over 1 to 8 months failed to elicit response (no change or progression).
28. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF. A pilot trial of vitaxin, a humanized anti-vitronectin receptor (anti αvβ3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm (2001) 16(2):125-132.
29. Wilder RL: Integrin αvβ3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis (2002) 61(Suppl 2):ii96-ii99.
30. Dechantsreiter MA, Planker E, Mathä B, Lohof E, Hölzemann G, Jonczyk A, Goodman SL, Kessler H: N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists. J Med Chem (1999) 42(16):3033-3040.
31. Goodman SL, Hölzemann G, Sulyok GA, Kessler H: Nanomolar small molecule inhibitors for αvβ6, αvβ5, and αvβ3 integrins. J Med Chem (2002) 45(5):1045-1051.
32. Sorbera LA, Graul A, Castañer J: Cilengitide. Drugs Future (2000) 25(7):674-678.
33. MacDonald TJ, Taga T, Shimida H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE: Preferential susceptibility of brain tumors to the anti-angiogenic effects of an αv integrin antagonist. Neurosurgery (2001) 48(1):151-157. After daily intraperitoneal administration of cilengitide to mice xenotransplanted intracranially with human medulloblastoma (DAOY) or glioblastoma (U87 MG) cell lines, animals appear to be cured and survive without evidence of morbidity.
34. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M: Inhibition of the α-v integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumors in vivo. Br J Cancer (2002) 86(5):788-795.
35. Bader BL, Rayburn H, Crowley D, Hynes RO: Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins. Cell (1998) 95(4):507-519. Vascular defects (hemorrhages) are reported in the brain and intestine only, pointing to the preferential involvement of αv integrins at these sites during embryonic development.
36. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI, Laug WE: αv-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer (2002) 98(5):690-697. In vitro studies indicate the effect of cilengitide as a promoter of cell death when the two brain tumor cell lines DAOY and U87 MG are grown on vitronectin and tenascin. To validate the concept of tumor cell-expressed αv participation in vivo, the authors also implanted M21 human melanoma cells, a model affording both αv-positive and αv-negative variants. Incidentally, αv expression did not confer enhanced survival per se in this model (untreated animals in both groups survived similarly), but integrin antagonism prolonged survival.
37. Lode HN, Moehler T, Xiang R, Jonczyk A, Gilles SD, Cheresh DA, Reisfeld RA: Synergy between an anti-angiogenic integrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci USA (1999) 96(4):1591-1596.
38. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL: Cilengitide targeting of αvβ3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res (2002) 62(15):4263-4272.
39. Nabors LB, Rosenfeld SS, Mikkelson T, Batcherlor T, Olson J, Grossman S, Piantadosi S, Fisher JD: A phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. J Neuro Oncol (2002) 4(4):Abs 236.
40. Eskens F, Dumez H, Verweij J, Brindley C, Perschl A, Kovar A, Wynendaele W, Van Oosterom A: Cilengitide (EMD 121974) inhibits angiogenesis by blocking αvβ3 and αvβ5 integrins; Mature results of a phase I and pharmacological study. Clin Cancer Res (2000) 6(Suppl):Abs 296.
41. Eskens F, Dumez H, Verweij J, Perschl A, Kovar A, Brindley C, Van Oosterom A: Phase I and pharmacologic study of EMD 121974, an αvβ3 and αvβ5 integrin inhibitor that perturbs tumor angiogenesis, in patients with solid tumors. Proc Am Soc Clin Oncol (2000) 19:Abs 801.
42. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, Van Oosterom AT: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours. Eur J Cancer (2003) 39(7):917-926.
43. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA: Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist. J Clin Invest (1999) 103(1):47-54.
44. Livant DL, Brabeck RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, Upadhyaya A: Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res (2000) 60(2):309-320.
45. Plunkett ML, Tel-Tsur Z, Bera M, Avery J, Livant DL, Mazar AP: A novel anti-angiogenic/anti-metastatic peptide, ATN-161 (Ac-PHSCN-NH2), which targets multiple fully activated integrins including α5 β1 and αv β-3, leads to increased anti-tumor activity and increased survival in multiple tumor models when combined with chemotherapy. Eur J Cancer (2002) 38(Suppl 7):Abs 249.
46. Plunkett ML, Mazar AP: Dose and schedule optimization of a novel anti-angiogenic/anti-metastatic petide, ATN-161 (Ac-PHSCN-NH2), which targets multiple fully activated integrins including α-5 β-1 and α-v β-3. Eur J Cancer (2002) 38(Suppl 7):Abs 262
47. Hartman GD, Duggan ME: αvβ3 Integrin antagonists as inhibitors of bone resorption. Expert Opin Investig Drugs (2000) 9(6):1281-1291.
48. Miller WH, Keenan RM, Willette RN, Lark MW: Identification and in vivo efficacy of small-molecule antagonists of integrin αvβ3 (the vitronectin receptor). Drug Disc Today (2000) 5(9):397-408.
49. Coleman PJ, Duong LT: Ligands to the integrin receptor αvβ3. Expert Opin Ther Patents (2002) 12(7):1009-1021.
50. Henry C, Moitessier N, Chapleur Y: Vitronectin receptor-αvβ3 integrin-antagonists: Chemical and structural requirements for activity and selectivity. Mini Rev Med Chem (2002) 2(6):531-542.
51. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, Arnaout MA: Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science (2002) 296(5565):151-155.
52. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL, Arnaout MA: Crystal structure of the extracellular segment of integrin αvβ3. Science (2001) 294(5541):339-345.
53. Gottschalk KE, Kessler H: The structure of integrins and integrin-ligand complexes: Implications for drug design and signal transduction. Angew Chem Int Ed (2002) 41(20):3767-3774.
54. Gottschalk KE, Günther R, Kessler H: A three-state mechanism of integrin activation and signal transduction for integrin αvβ3. Chemobiochem (2002) 3(5):470-473.
55. Arnaout MA, Goodman SL, Xiong JP: Coming to grips with integrin binding to ligands. Curr Opin Cell Biol (2002) 14(5):641-651.
56. Springer TA: Predicted and experimental structures of integrins and β-propellers. Curr Opin Struct Biol (2002) 12(6):802-813.
57. 214 of the β3 subunit and the basic nitrogen of the ligands interacting with the 7alpha;v subunit. An additional binding interaction, a π-π stacking with a Tyr of the αv subunit, correlates with improved activity.
58. Ruoslahti E: Drug targeting to specific vascular sites. Drug Disc Today (2002) 7(22):1138-1143.
59. Pasqualini R, Koivunen E, Ruoslahti E: αv Integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol (1997) 15(6):542-546.
60. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC: Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging. Nat Med (1998) 4(5):623-626. Coupling the LM-609 antibody with a paramagnetic contrast agent allowed efficient visualization of a tumor and its angiogenic hot spots by magnetic resonance imaging.
61. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 61(5):1781-1785.
62. Zitzmann S, Ehemann V, Schwab M: Arginine-Glycine-Aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res (2002) 62(18):5139-5143.
63. Arap W, Pasqualini R, Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 279(5349):377-380. Coupling the cytotoxic drug doxorubicin to a cyclic RGD peptide enhanced its efficacy and reduced its toxicity.
64. Chen Y, Xu X, Hong S, Chen J, Liu N, Underhill CB, Creswell K, Zhang L: RGD-tachyplesin inhibits tumor growth. Cancer Res (2001) 61(6):2434-2438. Treatment with an RGD peptidic sequence prolonged with that of the antimicrobial peptide tachyplesin inhibited the proliferation of tumor and endothelial cells in vitro and reduced tumor growth of a human prostate cancer implanted on the chick chorioallantoic membrane and growth of a syngenic melanoma tumor in mice.
65. 2, was fused to an RGD homing sequence to provide selective intracellular entry of the non-toxic pro-apoptotic peptide. Mice carrying breast carcinoma xenografts survived longer after treatment.
66. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA: Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 296(5577):2404-2407. Regression of established tumors was obtained using lipid-based nanoparticles covalently coupled to a synthetic αvβ3 antagonist to deliver the gene of a mutant form of Raf-1, a component of a signaling pathway important for neovascularization.
67. De Groot FM, Broxterman HJ, Adams HP, Van Vliet A, Tesser GI, Elderkamp YW, Schraa AJ, Kok RJ, Molema G, Pinedo HM, Scheeren HW: Design, synthesis and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Mol Cancer Ther (2002) 1(11):901-911.
68. Castel S, Pagan R, Mitjans F, Piulats J, Goodman S, Jonczyk A, Huber F, Vilaro S, Reina M: RGD peptides and monoclonal antibodies, antagonists of αv-integrin, enter the cells by independent endocytic pathways. Lab Invest (2001) 81(12):1615-1626.
69. 2 complex administered intravenously induced a significant delay in tumor growth of an ovarian carcinoma grafted subcutaneously; yet the unlabeled compound was inactive (the number of injections may have been too low to produce an effect).
70. Janssen ML, Oyen WJG, Massuger LFAG, Frielink C, Dijkgraaf I, Edwards DS, Rajopadhye M, Corstens FHM, Boerman OC: Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm (2002) 17(6):641-646. Compared with the monomeric form, the bivalent interaction of a dimeric antagonist of αv integrins permits high tumor accumulation, but the monomer presents with a higher tumor-to-kidney ratio.
71. 2 was active in a glioma model implanted intracranially. This compound also reduced tumor burden when the tumor was grafted subcutaneously, contrary to the effect of cilengitide in the same model.
72. Kok RJ, Schraa AJ, Bos EJ, Moorlag HE, Ásgeirsdóttir SA, Everts M, Meijer DK, Molema G: Preparation and functional evaluation of RGD-modified proteins as αvβ3 integrin directed therapeutics. Bioconjug Chem (2002) 13(1):128-135. This paper demonstrates that complexes of irrelevant antibodies bearing multiple RGD sequences have increased affinity for their targets when compared with free peptides.
73. Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK, De Leij LF, Molema G: Targeting of RGD-modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study. Int J Cancer (2002) 102(5):469-475. This paper demonstrates that complexes of irrelevant antibodies bearing multiple RGD sequences localize to the tumor endothelium and exhibit a longer half-life when compared with free RGD peptides.
74. Schraa AJ, Kok RJ, Berendsen AD, Moorlag HE, Bos EJ, Meijer DK, De Leij LF, Molema G: Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. J Control Release (2002) 83(2):241-251.
75. Madhusudan S, Harris AL: Drug inhibition of angiogenesis. Curr Opin Pharmacol (2002) 2(4):403-414.
76. Teti A, Migliaccio S, Baron R: The role of the αvβ3 integrin in the development of osteolytic bone metastases: A pharmacological target for alternative therapy? Calcif Tissue Int (2002) 71(4):293-299.
77. Brassard DL, Maxwell E, Malkowski M, Nagabhushan TL, Kumar CC, Armstrong L: Integrin αvβ3-mediated activation of apoptosis. Exp Cell Res (1999) 251(1):33-45.
78. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA: Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol (2001) 155(3):459-470.
79. Chatterjee S, Brite KH, Matsumura A: Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides. Clin Cancer Res (2001) 7(10):3006-3011.
80. Burbridge MF, Venot V, Casara PJ, Perron-Sierra F, Hickman JA, Tucker GC: Decrease in survival threshold of quiescent colon carcinoma cells in the presence of a small molecule integrin antagonist. Mol Pharmacol (2003) 63(6):1281-1288.
81. Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C, Dedhar S: αv integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene (2003) 22(11):1688-1702.
82. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 2(10):727-739.
83. Garber K: Angiogenesis inhibitors suffer new setback. Nat Biotechnol (2002) 20(11):1067-1068.
84. McCarty MF, Liu W, Fan F, Parikh A, Reimuth N, Stoeltzing N, Stoeltzing O, Ellis LM: Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends Mol Med (2003) 9(2):53-58.
85. Allman R, Cowburn P, Mason M: In vitro and in vivo effects of a cyclic peptide with affinity for the αvβ3 integrin in human melanoma cells. Eur J Cancer (2000) 36(3):410-422.
86. Takagi J, Petre BM, Walz T, Springer TA: Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell (2002) 110(5):599-611.
87. Legler DF, Wiedle G, Ross FP, Imhof BA: Superactivation of integrin αvβ3 by low antagonist concentrations. J Cell Sci (2001) 114(8):1545-1553.
88. Seftor RE, Seftor EA, Hendrix MJ: Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev (1999) 18(3):359-375.
89. Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M: Involvement of tumor cell integrin αvβ3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis (2002) 19(5):427-436.
90. Nash GF, Turner LF, Scully MF, Kakkar AK: Platelets and cancer. Lancet Oncol (2002) 3(7):427-430.
91. Schaffner P, Dard MM: Structure and function of RGD peptides involved in bone biology. Cell Mol Life Sci (2003) 60(1):119-132.
92. Cheresh DA, Stupack DG: Integrin-mediated death: An explanation of the integrin knockout phenotype? Nat Med (2002) 8(3):193-194.
93. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM: Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat Med (2002) 8(1):27-34.